Anti-Human Epidermal Growth Factor Receptor (EGFR)

Pricing & Details

Product No.E100
Clone
EGFR.1
Protein
Epidermal Growth Factor Receptor
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
ERBB, ERBB1, mENA
Isotype
Mouse
IgG2b κ
Applications
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
E100-0.25 mg
0.25 mg
$255.00
In stock
Max:
Min: 1
Step: 1

Data

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Mouse
Immunogen
A431 cultured cells
Product Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-Human EGFR recognizes the (Mr 170 kDa) extracellular domain of the epidermal growth factor receptor on many cell surfaces. The EGFR mediates the initial response of cells to EGF. It has an extracellular region which binds EGF and an intracellular region which exhibits tyrosine kinase activity.1 The receptor phosphorylates a number of protein substrates in addition to mediating autophosphorylation of tyrosine residues located near its carboxyl terminus.2,3
Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα) (note, a full list of the ligands able to activate EGFR and other members of the ErbB family is given in the ErbB article). ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as EGFR. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer - although there is some evidence that preformed inactive dimers may also exist before ligand binding. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers.

Antigen Details

Research Area
Cell Biology
.
Immunology
.
Innate Immunity
.
Neuroscience
.
Synaptic Biology

References & Citations

1. Berger, SM. et al. (1987) J. of Pathology 152:297
2. Downward, J. et al. (1984) Nature 311:483
3. Gullick, WJ. et al. (1985) EMBO J. 4:2869
4. Gullick, WJ. et al. (1986) Cancer Research 46:285
5. Gullick, WJ. et al. (1991) Br. Med. Bulletin 47:87
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.